GlassScriptPhysician profile
Paula U Ohiku
NPI 1215185327
$1,615.03
in general payments reported to CMS, 2019-2025
18 companies · $749 in 2025
The $749 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $343 · 2023: $97.97 · 2024: $259 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026 · Education: $79.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.41 |
| Education | $79.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248.10 | 2021-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $229.08 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $225.06 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $206.10 | 2025 | Uzedy |
| Indivior INC. | $121.78 | 2022-2025 | Sublocade |
| Lundbeck LLC | $106.61 | 2024-2025 | Abilify Asimtufii, Abilify Maintena |
| Phadia US INC. | $89.96 | 2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $62.76 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Exact Sciences Corporation | $54.68 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.31 | 2023-2025 | Caplyta |
| Globus Medical, INC. | $38.65 | 2025 | Senza |
| Janssen Biotech, INC. | $35.68 | 2023 | Simponi, Simponi Aria, Remicade |
| Axsome Therapeutics, INC. | $31.29 | 2025 | Auvelity |
| Gilead Sciences, INC. | $30.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.55 | 2025 | Invega Sustenna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.58 | 2024 | |
| Neurocrine Biosciences, INC. | $22.26 | 2023 | Ingrezza |
| Lilly USA, LLC | $19.22 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Ohiku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.